Founder Effect of the RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study
- PMID: 29020875
- DOI: 10.1089/thy.2017.0404
Founder Effect of the RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study
Abstract
Background: Multiple endocrine neoplasia (MEN) 2A and 2B are caused by REarranged during Transfection (RET) germline mutations. In a recent nationwide study, an unusually high prevalence (33%) of families with the C611Y mutation was reported, and it was hypothesized that this might be due to a founder effect. The first nationwide study of haplotypes in MEN2A families was conducted, with the aim of investigating the relatedness and occurrence of de novo mutations among Danish families carrying similar mutations.
Methods: The study included 21 apparently unrelated MEN2A families identified from a nationwide Danish RET cohort from 1994 to 2014. Twelve, two, two, three, and two families carried the C611Y, C618F, C618Y, C620R, and C634R mutations, respectively. Single nucleotide polymorphism chip data and identity by descent analysis were used to assess relatedness.
Results: A common founder mutation was found among all 12 C611Y families and between both C618Y families. No relatedness was identified in the remaining families.
Conclusion: The data suggest that all families with the C611Y germline mutation in Denmark originate from a recent common ancestor, probably explaining the unusually high prevalence of this mutation. Additionally, the results indicate that the C611Y mutation rarely arises de novo, thus underlining the need for thorough multigenerational genetic work up in carriers of this mutation.
Keywords: C611Y; Cys611Tyr; Denmark; REarranged during Transfection (RET); founder effect; multiple endocrine neoplasia 2A (MEN2A).
Similar articles
-
Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.Thyroid. 2017 Feb;27(2):215-223. doi: 10.1089/thy.2016.0411. Epub 2017 Jan 13. Thyroid. 2017. PMID: 27809725 Free PMC article.
-
Familial prevalence and age of RET germline mutations: implications for screening.Clin Endocrinol (Oxf). 2008 Jul;69(1):81-7. doi: 10.1111/j.1365-2265.2007.03153.x. Epub 2008 Jul 1. Clin Endocrinol (Oxf). 2008. PMID: 18062802
-
RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.Clin Endocrinol (Oxf). 2007 Oct;67(4):570-6. doi: 10.1111/j.1365-2265.2007.02927.x. Epub 2007 Jun 15. Clin Endocrinol (Oxf). 2007. PMID: 17573899
-
Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.Eur J Endocrinol. 2008 Dec;159(6):767-71. doi: 10.1530/EJE-08-0476. Epub 2008 Sep 19. Eur J Endocrinol. 2008. PMID: 18805915 Review.
-
RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):57-61. doi: 10.6061/clinics/2012(sup01)11. Clinics (Sao Paulo). 2012. PMID: 22584707 Free PMC article. Review.
Cited by
-
Applications of genomic research in pediatric endocrine diseases.Clin Exp Pediatr. 2023 Dec;66(12):520-530. doi: 10.3345/cep.2022.00948. Epub 2023 Jun 14. Clin Exp Pediatr. 2023. PMID: 37321569 Free PMC article.
-
Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective Study.Cancers (Basel). 2023 Apr 2;15(7):2125. doi: 10.3390/cancers15072125. Cancers (Basel). 2023. PMID: 37046785 Free PMC article.
-
Multiple endocrine neoplasia 2: an overview.Ther Adv Chronic Dis. 2022 Feb 25;13:20406223221079246. doi: 10.1177/20406223221079246. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35237400 Free PMC article. Review.
-
Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.Croat Med J. 2021 Apr 30;62(2):110-119. doi: 10.3325/cmj.2021.62.110. Croat Med J. 2021. PMID: 33938650 Free PMC article.
-
Preimplantation Genetic Testing of Multiple Endocrine Neoplasia Type 2A.Front Endocrinol (Lausanne). 2020 Oct 14;11:572151. doi: 10.3389/fendo.2020.572151. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33178136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
